These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
412 related articles for article (PubMed ID: 27449665)
1. Impact of quadrivalent influenza vaccine on public health and influenza-related costs in Australia. Jamotte A; Chong CF; Manton A; Macabeo B; Toumi M BMC Public Health; 2016 Jul; 16():630. PubMed ID: 27449665 [TBL] [Abstract][Full Text] [Related]
2. Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine. Reed C; Meltzer MI; Finelli L; Fiore A Vaccine; 2012 Mar; 30(11):1993-8. PubMed ID: 22226861 [TBL] [Abstract][Full Text] [Related]
3. Public health impact and economic benefits of quadrivalent influenza vaccine in Latin America. Jamotte A; Clay E; Macabeo B; Caicedo A; Lopez JG; Bricks L; Romero Prada M; Marrugo R; Alfonso P; Moreno Arévalo B; Franco D; Garcia Diaz L; Isaza de Molto Y Hum Vaccin Immunother; 2017 Apr; 13(4):877-888. PubMed ID: 28118092 [TBL] [Abstract][Full Text] [Related]
4. Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years. Kieninger D; Sheldon E; Lin WY; Yu CJ; Bayas JM; Gabor JJ; Esen M; Fernandez Roure JL; Narejos Perez S; Alvarez Sanchez C; Feng Y; Claeys C; Peeters M; Innis BL; Jain V BMC Infect Dis; 2013 Jul; 13():343. PubMed ID: 23883186 [TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of quadrivalent versus trivalent influenza vaccine in Taiwan: A lifetime multi-cohort model. Yang MC; Tan EC; Su JJ Hum Vaccin Immunother; 2017 Jan; 13(1):81-89. PubMed ID: 27624648 [TBL] [Abstract][Full Text] [Related]
6. Public health and economic impact of seasonal influenza vaccination with quadrivalent influenza vaccines compared to trivalent influenza vaccines in Europe. Uhart M; Bricout H; Clay E; Largeron N Hum Vaccin Immunother; 2016 Sep; 12(9):2259-68. PubMed ID: 27166916 [TBL] [Abstract][Full Text] [Related]
7. A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years. Domachowske JB; Pankow-Culot H; Bautista M; Feng Y; Claeys C; Peeters M; Innis BL; Jain V J Infect Dis; 2013 Jun; 207(12):1878-87. PubMed ID: 23470848 [TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness evaluation of quadrivalent influenza vaccines for seasonal influenza prevention: a dynamic modeling study of Canada and the United Kingdom. Thommes EW; Ismaila A; Chit A; Meier G; Bauch CT BMC Infect Dis; 2015 Oct; 15():465. PubMed ID: 26503131 [TBL] [Abstract][Full Text] [Related]
9. From trivalent to quadrivalent influenza vaccines: Public health and economic burden for different immunization strategies in Spain. Crépey P; Redondo E; Díez-Domingo J; Ortiz de Lejarazu R; Martinón-Torres F; Gil de Miguel Á; López-Belmonte JL; Alvarez FP; Bricout H; Solozabal M PLoS One; 2020; 15(5):e0233526. PubMed ID: 32437476 [TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of quadrivalent influenza vaccine in Spain. García A; Ortiz de Lejarazu R; Reina J; Callejo D; Cuervo J; Morano Larragueta R Hum Vaccin Immunother; 2016 Sep; 12(9):2269-77. PubMed ID: 27184622 [TBL] [Abstract][Full Text] [Related]
11. Retrospective public health impact of a quadrivalent influenza vaccine in the United States. Crépey P; de Boer PT; Postma MJ; Pitman R Influenza Other Respir Viruses; 2015 Aug; 9 Suppl 1(Suppl 1):39-46. PubMed ID: 26256294 [TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of quadrivalent influenza vaccine in Hong Kong - A decision analysis. You JH; Ming WK; Chan PK Hum Vaccin Immunother; 2015; 11(3):564-71. PubMed ID: 25714506 [TBL] [Abstract][Full Text] [Related]
13. Impact of quadrivalent influenza vaccines in Brazil: a cost-effectiveness analysis using an influenza transmission model. Crépey P; Boiron L; Araujo RR; Lopez JG; Petitjean A; de Albuquerque Luna EJ BMC Public Health; 2020 Sep; 20(1):1374. PubMed ID: 32907562 [TBL] [Abstract][Full Text] [Related]
14. Immunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged ≥18 years: a phase III, randomized trial. Tinoco JC; Pavia-Ruz N; Cruz-Valdez A; Aranza Doniz C; Chandrasekaran V; Dewé W; Liu A; Innis BL; Jain VK Vaccine; 2014 Mar; 32(13):1480-7. PubMed ID: 24486352 [TBL] [Abstract][Full Text] [Related]
15. Quadrivalent Influenza Vaccine-Induced Antibody Response and Influencing Determinants in Patients ≥ 55 Years of Age in the 2018/2019 Season. Ganczak M; Dubiel P; Drozd-Dąbrowska M; Hallmann-Szelińska E; Szymański K; Brydak LB Int J Environ Res Public Health; 2019 Nov; 16(22):. PubMed ID: 31739554 [TBL] [Abstract][Full Text] [Related]
16. Cost Effectiveness of Quadrivalent Influenza Vaccines Compared with Trivalent Influenza Vaccines in Young Children and Older Adults in Korea. Kim YK; Song JY; Jang H; Kim TH; Koo H; Varghese L; Han E Pharmacoeconomics; 2018 Dec; 36(12):1475-1490. PubMed ID: 30251078 [TBL] [Abstract][Full Text] [Related]
17. Comparison of the immunogenicity and safety of quadrivalent and tetravalent influenza vaccines in children and adolescents. Huang C; Fu X; Zhou Y; Mi F; Tian G; Liu X; Wu J; Ding C; Yan D; Li L; Yang S Vaccine; 2020 Feb; 38(6):1332-1344. PubMed ID: 31948819 [TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness of Quadrivalent versus Trivalent Influenza Vaccine in the United States. de Boer PT; Crépey P; Pitman RJ; Macabeo B; Chit A; Postma MJ Value Health; 2016 Dec; 19(8):964-975. PubMed ID: 27987647 [TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and safety of an egg-based inactivated quadrivalent influenza vaccine (GC3110A) versus two inactivated trivalent influenza vaccines with alternate B strains: A phase Ⅲ randomized clinical trial in adults. Song JY; Lee J; Woo HJ; Wie SH; Lee JS; Kim SW; Kim TH; Jung SI; Noh JY; Choi WS; Cheong HJ; Kim WJ Hum Vaccin Immunother; 2019; 15(3):710-716. PubMed ID: 30396317 [TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and Safety of an Inactivated Quadrivalent Influenza Vaccine in US Children 6-35 Months of Age During 2013-2014: Results From A Phase II Randomized Trial. Wang L; Chandrasekaran V; Domachowske JB; Li P; Innis BL; Jain VK J Pediatric Infect Dis Soc; 2016 Jun; 5(2):170-9. PubMed ID: 26407273 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]